LONDON (AFX) - Abcam PlC, which markets antibodies via an online catalogue
, said it has acquired sole distribution rights of a product line 46 immunology research antibodies from Fusion Antibodies Ltd for an undisclosed sum.
The agreement consists of a purchase of existing inventory of the antibodies and the rights for Abcam to convert this agreement from sole distribution into exclusive distribution for a small fee per antibody over the next seven years.
Abcam said the antibodies bought from Fusion allow it to expand in areas such as assay testing kits, the company added.
'This type of product acquisition enables us to take advantage of high margin products and we consider this transaction to complement our recently announced plans to increase our own production with a high throughput laboratory,' said CEO Jonathan Milner.
COPYRIGHT Copyright AFX News Limited 2006. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.